Sort by
Keyphrases
Clinical Management
100%
Pediatric Population
100%
Pediatric
100%
Amphotericin B
100%
Cutaneous Leishmaniasis
100%
Diagnosis Management
100%
Meglumine Antimoniate
100%
Miltefosine
100%
Case-based Approach
100%
Clinical Presentation
66%
Species Identification
66%
Therapeutic Challenges
66%
Diagnostic Challenge
66%
Treatment Outcome
66%
Tolerability
33%
Diagnostic Interventions
33%
Clinical Manifestations
33%
Immune Response
33%
Pediatric Patients
33%
Severe Disease
33%
Panama
33%
Diagnostic Approach
33%
Causative Agents
33%
Polymerase Chain Reaction
33%
Localized Cutaneous Leishmaniasis
33%
Gene Sequencing
33%
Treatment Protocol
33%
Neglected Tropical Diseases
33%
Follow-up Examination
33%
Histological Analysis
33%
Polymerase Chain Reaction Analysis
33%
Leishmania Panamensis
33%
Nodular Lesion
33%
Pediatric Case
33%
Treatment Resistance
33%
Ulcerative Lesions
33%
Heat Shock Protein 70 Gene
33%
Species Response
33%
Leishmania Guyanensis
33%
Disseminated Cutaneous Leishmaniasis
33%
Intermediate Forms
33%
Pharmacodynamic Difference
33%
Treatment Optimization
33%
Lesion Progression
33%
Mucocutaneous Leishmaniasis
33%
Pharmacokinetic Differences
33%
Mucosal Sites
33%
Medicine and Dentistry
Pediatrics
100%
Cutaneous Leishmaniasis
100%
Clinical Management
100%
Amphotericin B
50%
Miltefosine
50%
Meglumine Antimoniate
50%
Polymerase Chain Reaction
33%
Leishmania
33%
Pediatrics Patient
16%
Immune Response
16%
Neglected Tropical Diseases
16%
Gene Sequence
16%
Pharmacokinetic
16%
Pharmacodynamics
16%
Heat Shock Protein 70
16%
Pharmacology, Toxicology and Pharmaceutical Science
Skin Leishmaniasis
100%
Amphotericin B
50%
Miltefosine
50%
Meglumine
50%
Tolerability
16%
Pharmacodynamics
16%
Pharmacokinetic
16%
Tropical Disease
16%
Leishmania panamensis
16%
Leishmania guyanensis
16%
Heat Shock Protein 70
16%
Immunology and Microbiology
Cutaneous Leishmaniasis
100%
Meglumine Antimoniate
50%
Species Identification
33%
Polymerase Chain Reaction
33%
Immune Response
16%
Gene Sequence
16%
Leishmania panamensis
16%
Heat Shock
16%
Leishmania guyanensis
16%
Pharmacodynamics
16%
Pharmacokinetic
16%